Compared side by side
Tirzepatide vs eloralintide: how they differ
The short answer
They act on different hormones: tirzepatide activates the GLP-1 and GIP receptors, and eloralintide is a selective agonist of the amylin receptor, the receptor for the fullness hormone the pancreas releases with insulin. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; eloralintide, from Eli Lilly, has been in phase 3 since late 2025 and isn’t approved anywhere. Both are weekly shots, and in their own trials tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1), and eloralintide’s 9 mg about 20% at 48 weeks in phase 2.
Side by side
| Compared | Tirzepatide | Eloralintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | LY3841136, Elora |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | Once-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | In trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | Research range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~14 days (measured in people: phase 1 trials, Bhattachar 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | Used continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction |
- Category
- TirzepatideMetabolic & GLP-1
- EloralintideMetabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- EloralintideLY3841136, Elora
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- EloralintideA once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- EloralintideOnce-weekly, long-acting agonist of the amylin receptor, the receptor for amylin, the fullness hormone the pancreas releases with insulin. Unlike cagrilintide, it is selective: it acts far more on amylin receptors than on the calcitonin receptor, a difference Lilly thinks may make it easier on the stomach. The idea is fewer calories through earlier fullness after meals rather than through the GLP-1 pathway. Its half-life of about 14 days keeps blood levels nearly flat across the week. Investigational, from Eli Lilly, in phase 3 since late 2025.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- EloralintideIn trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. It is in phase 3 and not approved anywhere.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- EloralintideResearch range: 1–9 mg, starting dose 3 mg. Studied in research — not a recommendation.
- How often
- TirzepatideWeekly
- EloralintideWeekly
- Half-life
- Tirzepatide~5 days (FDA label)
- Eloralintide~14 days (measured in people: phase 1 trials, Bhattachar 2026)
- Route
- TirzepatideSubQ injection
- EloralintideSubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- EloralintideUsed continuously, once weekly, in its trials: 12 weeks in phase 1 and 48 weeks in phase 2; phase 3 runs about 75 weeks. No trial has tested stopping it.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- EloralintideModerate: animal studies + some human data
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- EloralintideNausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Eloralintide
- Day 1–28 · 3 mg Fullness first, gently
- Day 29–56 · 6 mg The step where nausea shows up
- Day 57–336 · 6 mg Holding at 6 mg
- Day 57–336 · 9 mg The top dose tested
- Day 85–336 Fewer cravings, quieter food noise
- Day 337+ A long-term medicine, not a course
Together or one or the other
Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks.
RCT · Eloralintide
Eloralintide with tirzepatide
Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.
Questions people ask
How long do tirzepatide and eloralintide last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of eloralintide is ~14 days (measured in people: phase 1 trials, Bhattachar 2026).
How often are tirzepatide and eloralintide taken?
Tirzepatide: weekly. Route: SubQ injection. Eloralintide: weekly. Route: SubQ injection.
How are tirzepatide and eloralintide dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for eloralintide is 1–9 mg, with a 3 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of tirzepatide and eloralintide?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For eloralintide: nausea, fatigue, constipation, diarrhea, vomiting, decreased appetite, hair thinning, injection site reaction.
Are tirzepatide and eloralintide taken together?
Tirzepatide and eloralintide are a common stack: eloralintide lists tirzepatide among its common stacks. Lilly is testing the two together as EloraTZP, amylin plus GIP and GLP-1. In a 48-week trial in type 2 diabetes, the top pair averaged about 23% weight loss vs about 15% on tirzepatide alone. Side effects were more common in the pairs, mostly while doses were stepping up.